Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELOâ„¢ ...
The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course. Polivy (polatuzumab vedotin-piiq) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback